P erformance variation is easy to find-all one needs to do is to look for it. We have long known that some nations achieve better control of hypertension than others, 1 some hospitals have shorter door-to-balloon times than others, 2 and some cardiac surgeons have better risk-adjusted mortality after coronary artery bypass graft surgery than others.
erformance variation is easy to find-all one needs to do is to look for it. We have long known that some nations achieve better control of hypertension than others, 1 some hospitals have shorter door-to-balloon times than others, 2 and some cardiac surgeons have better risk-adjusted mortality after coronary artery bypass graft surgery than others. 3 In fact, it is difficult to recall an instance when performance was found not to vary. Given that performance variation is ubiquitous, it is no longer shocking to find it; the more interesting question is why performance varies so much. The answer to this question would likely be a key step along the pathway to improving performance.
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It is rather uncommon to find a single answer to the question of why performance variation exists. However, in the current issue of Circulation, Van Spall and colleagues 4 have found an unusually straightforward explanation for performance variation, at least in the context of the management of warfarin. The authors found that site-level adherence to a relatively simple algorithm regarding when to change the dose of warfarin and when not to change the dose predicted fully 87% of between-center variance. Adding patient-level clinical variables (ie, risk-adjustment), center-level variables, and country-level variables only increased the amount of explained variation to 89%. In short, management of warfarin doses appeared to be almost deterministic regarding the anticoagulation control that was achieved. Remarkably, the authors also found that greater adherence to the algorithm also predicted a reduced rate of the combined primary end point of stroke, major hemorrhage, or death at the site level. For each 10% increase in algorithm-consistent dosing at the center level, the annual rate of the combined end point was 8% lower, even after adjusting for a host of patient-level predictors. The algorithm has additional attractive features as well, not least of which is that it does not require a computer or proprietary software to use. In fact, it would be equally suitable to use in developing countries.
The authors deftly used a feature of their dataset to demonstrate that percent time in therapeutic range (TTR) really is in the causal pathway to adverse events. Because their dataset was drawn from a randomized trial of dabigatran versus warfarin, they were able to show that, whereas sites with more algorithm-consistent warfarin dosing had lower rates of adverse events among patients receiving warfarin, they did not have lower rates of adverse events among patients receiving dabigatran. Some have expressed doubts about whether TTR really is in the causal pathway to outcomes, 5 suggesting that instead, sites with higher TTR also might be delivering high-quality care in other ways. If this were true, then quality improvement efforts aimed at increasing TTR might not achieve the desired benefits in terms of preventing adverse events. The finding by Van Spall and colleagues 4 serves as a strong refutation for this line of reasoning, because if high-TTR sites were truly delivering other interventions responsible for preventing adverse events, we would have seen a similar reduction in adverse events among patients receiving dabigatran. The present study therefore serves as a strong endorsement of efforts to improve TTR at the site level and thereby prevent adverse events.
The algorithm studied by Van Spall and colleagues 4 was similar to others that are in widespread use. The algorithm suggested no dose change for an in-range international normalized ratio (INR) value, a 10% dose change when the INR was somewhat out of range (1.51-1.99 or 3.01-4.00), and a 15% dose change for greater deviations from the target range. The authors note that, although they distributed this algorithm, they cannot know to what extent the sites of care actually used it-in essence, their study examined the difference between care that would have been algorithmconcordant, as the authors put it, "whether intentionally or not." In a study by Kim et al, 6 a very similar (but not completely identical) dosing algorithm was shown to improve TTR. The Kim study complements the current study in that it shows that the introduction of a standardized dosing algorithm improved TTR considerably using a before-after design. 6 Although Van Spall and colleagues were able to show that algorithm-concordant care was important, they were unable to examine whether the introduction of the algorithm had actually increased the likelihood that such care would be delivered. Also, in the Kim study, algorithm-consistent dosing was highly correlated with patient-level TTR, which complements the site-level findings of the current study. Taken together, the 2 studies suggest that the algorithm is both valid (in the sense of predicting important outcomes) 4 and feasible (in the sense that it can successfully be introduced and change clinical practice). 6 The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
From Any algorithm for warfarin dose management, whether paper-based or computer-based, needs to be introduced with a caveat, namely that the clinician must always have the power to override the algorithm. Any decision about warfarin dose changes must occur in the context of the visit, and some information that is divulged by the patient (for example, recent dietary intake) may well prompt a decision that is discordant with the algorithm. 7 However, both the Van Spall and Kim studies strongly suggest that clinicians managing warfarin should ask themselves whether they really have a compelling reason to deviate from the algorithm-and then ask again for good measure.
The present study also adds to a growing discussion about how to manage warfarin doses when the INR is only slightly out of range. In the past, several studies have suggested that dose changes are not necessary for mildly deranged INR, and in fact may begin a cycle of overcorrection and rebound that may worsen control. 8 -9 Based on this limited evidence, the latest consensus guidelines for managing warfarin suggest not changing the dose when the INR deviates by Յ0.5 from the target range, and instead merely rechecking in 1 to 2 weeks. 10 Notably, a deviation of up to 0.5 is an even wider tolerance range than would be suggested by either of the previous studies. 8 -9 With this issue in mind, Van Spall and colleagues examined whether their findings would also be true when the tolerance range was widened from 2.0 to 3.0 to 1.9 to 3.1, 1.8 to 3.2, 1.7 to 3.3, and 1.6 to 3.4. They found that TTR was higher with increased adherence to any of these ranges, but was best with the strict construction of the target range (ie, 2.0 -3.0). In addition, only the strict construction predicted the primary combined end point in a statistically significant fashion. Thus, the findings of the present study cast at least some doubt on the idea of a widened tolerance range, within which slightly deranged INR values do not prompt a dose change. Ideally, a well-designed prospective study could address this issue more definitively. For now, although some clinicians may still opt to have a tolerance range, it may be prudent not to extend it beyond approximately 1.8 to 3.2, 8 -9 as opposed to the much wider range of 1.5 to 3.5 recommended by the most recent guidelines. 10 One noteworthy limitation of the present study stems from its origins in a clinical trial. 11 The patients represented in this study may have been unusually adherent to their medication, and gaps in INR monitoring were likely minimal. In a real-world setting, dose management may not predict 87% of site variation, and other issues, like gaps in INR monitoring, also may play an important role. Our group has shown that nonstandard target ranges, gaps in INR monitoring, and failure to recheck INR promptly after an out-of-range value are also strong predictors of site-level TTR. [12] [13] [14] Together, these 3 measures predicted 48% of TTR variation among sites of care in the Veterans Health Administration (our unpublished finding). It is likely, therefore, that although adherence to the algorithm examined by Van Spall and colleagues may be the single most important determinant of site-level TTR, it is not the only performance measure worth addressing. In fact, improving TTR is likely to require a multifactorial approach, as there are many related issues that contribute to TTR (Table) .
Another limitation, mentioned above, is that the present study was not an attempt to actually implement the algorithm under study. Kim and colleagues successfully implemented a similar algorithm, 6 but they did so at a single site of care, which may not be representative of other sites. An important next step would be a prospective test of this algorithm in a real-world setting, preferably across an integrated health system. Such an effort would require great attention to the principles of implementation science to promote successful adoption of the algorithm. 15 In fact, we have recently begun such a study in the New England region of the Veterans Health Administration. One challenge for our effort, and for any effort occurring in the real world, is that automated data may not reliably identify dose changes in warfarin, which is usually prescribed as use as directed. A need to rely on chart review to track adherence to the algorithm may hamper efforts to measure its uptake. In summary, Van Spall and colleagues 4 have added several important new pieces of information to the literature. First, in combination with other studies, 6 the present study convincingly demonstrates that managing warfarin according to a standard algorithm can improve patient outcomes. Second, it should lay to rest any lingering doubts about whether TTR is truly in the causal pathway to adverse events. Finally, it suggests that changing the dose of warfarin for any out-ofrange INR may in fact be best, although other studies have found differently, 8 -9 and further evidence is needed. The study by Van Spall and colleagues certainly provides a powerful argument for greater adoption of any sort of system to promote standardized dose management for warfarineither computer support when it is available, or paper-based algorithms if not. Improving outcomes for patients receiving warfarin will not be easy, but it may be easier than we think.
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